Letermovir denied for missing prior authorization by Humana?

Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Letermovir — and How to Get It Approved

Humana classifies letermovir as a specialty drug requiring prior authorization (PA) before it will be covered. A PA-required denial — or a PA that was submitted and denied — means Humana has not yet received or accepted the clinical documentation establishing that the patient meets its coverage criteria. This is one of the most straightforward denial types to resolve because the path forward is clearly defined: obtain Humana's PA criteria, document that the patient meets every element, and submit a complete request with a prescriber letter.

## The Federal Legal Framework

• ERISA §503: employer-sponsored plans must provide a full-and-fair review of a denied PA with written rationale identifying every unmet criterion.
• ACA §2719: if the PA is denied and the internal appeal fails, independent external review is available within approximately four months of denial. An expedited process applies when delay poses a risk to the patient's health — this is frequently applicable in post-transplant prophylaxis scenarios where the treatment window is time-limited.
• Urgent/expedited PA: Humana must process an expedited PA within 72 hours when the prescriber certifies that the standard timeframe would seriously jeopardize the patient's health or ability to regain maximum function.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's PA criteria for letermovir before submitting or resubmitting — call Humana's specialty pharmacy line or download the current clinical criteria document. 2. Submit or resubmit the PA with a complete documentation package (see below). Request expedited review given transplant urgency. 3. If denied: file a first-level internal appeal within the deadline in the denial letter. Request a peer-to-peer call between the prescriber and Humana's medical director. 4. External review: if internal appeals are exhausted, file for IRO review; PA denials for FDA-approved drugs in guideline-supported indications have high external-review reversal rates.

## Documentation to Gather

• Transplant documentation: operative or discharge summary confirming transplant type, date, and donor source — this is frequently the anchor criterion in Humana's PA policy.
• CMV serostatus: current laboratory reports for donor and recipient CMV IgG serostatus — often the single most important clinical criterion.
• Immunosuppression protocol: current medication list establishing the degree of immune compromise and the transplant team's ongoing management plan.
• Risk-stratification note: a chart note from the transplant physician or transplant infectious disease specialist documenting CMV risk category and explaining why prophylaxis is the chosen clinical strategy.
• Prescriber PA letter: a letter that maps every element of Humana's PA criteria to a specific finding in the patient's chart, references the relevant transplant guideline organization, and states the FDA-approved indication being treated.
• Urgency certification: if requesting expedited review, the prescriber must certify the clinical urgency in writing.

## Criteria-Mapping Structure

Humana's PA criteria for letermovir will list specific clinical requirements. Build a table in the PA request or appeal letter: left column, each Humana criterion; right column, the specific chart fact, lab date, or clinical note that satisfies it. Do not leave any criterion unaddressed. A complete, criteria-mapped PA submission with a strong prescriber letter is approved far more often than an incomplete one — and avoids the delay of an initial denial followed by an appeal cycle.